Pharsight

Vistogard patents expiration

VISTOGARD Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6258795 WELLSTAT THERAP Acylated uridine and cytidine and uses thereof
Jul, 2023

(2 months ago)

US7776838 WELLSTAT THERAP Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Aug, 2027

(3 years from now)

Vistogard is owned by Wellstat Therap.

Vistogard contains Uridine Triacetate.

Vistogard has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Vistogard are:

  • US6258795

Vistogard was authorised for market use on 11 December, 2015.

Vistogard is available in granule;oral dosage forms.

Vistogard can be used as emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adverse reactions within 96 hours.

The generics of Vistogard are possible to be released after 17 August, 2027.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 11, 2022

Drugs and Companies using URIDINE TRIACETATE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...

Dosage: GRANULE;ORAL

More Information on Dosage

VISTOGARD family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic